home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9409d.zip
/
M9490503.TXT
< prev
next >
Wrap
Text File
|
1994-09-24
|
3KB
|
45 lines
Document 0503
DOCN M9490503
TI Protein binding of human immunodeficiency virus protease inhibitor
KNI-272 and alteration of its in vitro antiretroviral activity in the
presence of high concentrations of proteins.
DT 9411
AU Kageyama S; Anderson BD; Hoesterey BL; Hayashi H; Kiso Y; Flora KP;
Mitsuya H; Experimental Retrovirology, Section, National Cancer
Institute,; Bethesda, Maryland 20892.
SO Antimicrob Agents Chemother. 1994 May;38(5):1107-11. Unique Identifier :
AIDSLINE MED/94346814
AB KNI-272 represents a peptide-based protease inhibitor having potent
antiretroviral activity against human immunodeficiency virus (HIV) in
vitro. The structure contains allophenylnorstatine
[(2S,3S)-3-amino-2-hydroxy-4-phenylbutyric acid] with a
hydroxymethylcarbonyl isostere. We asked whether this experimental
anti-HIV agent could exert its activity in vitro in the presence of
relatively high concentrations of fetal calf serum (FCS) and assessed
its protein-binding properties by using fresh human plasma preparations.
The 50 and 75% inhibitory concentrations of KNI-272 against HIV type 1
replication in vitro were 3- to 5-fold and 5-fold higher in the presence
of 50% FCS and 15- to 25-fold and 25- to 100-fold higher in the presence
of 80% ECS, respectively, than those with 15% FCS, whereas the antiviral
activity of 2',3'-dideoxyinosine was not significantly affected by FCS
concentrations in the culture. Detailed studies of the protein binding
of KNI-272 suggest that in human plasma binding occurs predominantly to
alpha 1-acid glycoprotein and that KNI-272 is probably extensively
(approximately 98 to 99%) protein bound at concentrations likely to be
achieved in the circulation. Thus, higher levels of KNI-272 in plasma
may be required when this compound undergoes clinical trials relative to
those inferred from in vitro data involving the use of 10 to 15%
FCS-containing culture media. The current data may have a relevance to
other antiretroviral drugs that are under development and that have a
high protein-binding capacity.
DE Animal Blood Proteins/METABOLISM Cattle Cells, Cultured Human HIV
Protease Inhibitors/BLOOD/PHARMACOLOGY/*PHARMACOKINETICS HIV-1/DRUG
EFFECTS Indicators and Reagents
Oligopeptides/BLOOD/PHARMACOLOGY/*PHARMACOKINETICS
Orosomucoid/METABOLISM Protein Binding Proteins/*PHARMACOLOGY
Retroviridae/*DRUG EFFECTS JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).